These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 6206311)

  • 21. Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.
    Fleming JS; Buchanan JO; Yocca FD; Iben LG; Antonaccio MJ
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):763-8. PubMed ID: 1909560
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Encainide: its electrophysiologic and antiarrhythmic effects, pharmacokinetics, and safety.
    Tordjman T; Estes NA
    Pharmacotherapy; 1987; 7(5):149-63. PubMed ID: 3124082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temperature and voltage dependence of sodium channel blocking and unblocking by O-demethyl encainide in isolated guinea pig myocytes.
    Johns JA; Anno T; Bennett PB; Snyders DJ; Hondeghem LM
    J Cardiovasc Pharmacol; 1989 Jun; 13(6):826-35. PubMed ID: 2484076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia.
    Ross DL; Sze DY; Keefe DL; Swerdlow CD; Echt DS; Griffin JC; Winkle RA; Mason JW
    Circulation; 1982 Dec; 66(6):1205-10. PubMed ID: 6814784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ibutilide on spontaneous and induced ventricular arrhythmias in 24-hour canine myocardial infarction: a comparative study with sotalol and encainide.
    Buchanan LV; Kabell G; Turcotte UM; Brunden MN; Gibson JK
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):256-63. PubMed ID: 1376795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of life-threatening ventricular tachycardia with encainide hydrochloride in patients with left ventricular dysfunction. The Encainide-Ventricular Tachycardia Study Group.
    Am J Cardiol; 1988 Sep; 62(9):571-5. PubMed ID: 3137797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Encainide in lethal ventricular arrhythmias evaluated by electrophysiologic testing and decrease in symptoms.
    Horowitz LN
    Am J Cardiol; 1986 Aug; 58(5):83C-86C. PubMed ID: 3092624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous 3-methoxy-O-desmethyl-encainide in reentrant supraventricular tachycardia: a randomized double-blind placebo-controlled trial in patients undergoing EP study.
    Ware DL; Lee JT; Murray KT; Hanyok JJ; Roden DM; Echt DS
    Pacing Clin Electrophysiol; 1991 Sep; 14(9):1343-50. PubMed ID: 1720527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Marked Q-T prolongation due to encainide therapy.
    Davies W; Jazayeri M; Tchou P
    Cardiovasc Drugs Ther; 1988 Sep; 2(3):283-6. PubMed ID: 3155328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Electrophysiological effects of encainide and its metabolites in 11 patients.
    Libersa CC; Lekieffre JP; Caron JF; Poirier JM; Pladys AM; Kacet S; Kher AR
    J Cardiovasc Pharmacol; 1985; 7(6):1077-82. PubMed ID: 2418291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of encainide for malignant ventricular arrhythmias.
    Tordjman T; Podrid PJ; Raeder E; Lown B
    Am J Cardiol; 1986 Aug; 58(5):87C-95C. PubMed ID: 3092625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of encainide and amiodarone on the adaptation of ventricular refractoriness to an increase in rate.
    Rosenheck S; Schmaltz S; Kadish AH; Morady F
    Am J Cardiol; 1990 Jul; 66(2):229-30. PubMed ID: 2115289
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of encainide (MJ9067) on the ventricular fibrillation threshold in anesthetized dogs.
    Jaillon P; de la Rosa S; Griffin JC; Winkle RA; Harrison DC
    J Cardiovasc Pharmacol; 1980; 2(5):517-26. PubMed ID: 6157946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encainide. A review of its pharmacological properties and therapeutic efficacy.
    Brogden RN; Todd PA
    Drugs; 1987 Nov; 34(5):519-38. PubMed ID: 3121275
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias.
    Winkle RA; Peters F; Kates RE; Tucker C; Harrison DC
    Circulation; 1981 Aug; 64(2):290-6. PubMed ID: 6788400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relation of blood level and metabolites to the antiarrhythmic effectiveness of encainide.
    Harrison DC; Kates RE; Quart BD
    Am J Cardiol; 1986 Aug; 58(5):66C-73C. PubMed ID: 3092622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The antiarrhythmic action of encainide versus ventricular arrhythmias in the conscious dog following coronary artery ligation.
    Byrne JE; Gomoll AW
    Can J Physiol Pharmacol; 1982 Mar; 60(3):369-75. PubMed ID: 6804074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
    Toivonen L; Kadish A; Morady F
    Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.